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We analyze the metabolomes of humans, chimpanzees and macaques in muscle, kidney and 
three different regions of the brain. Whereas several compounds in amino acid metabolism 
occur at either higher or lower concentrations in humans than in the other primates, 
metabolites in oxidative phosphorylation and purine biosynthesis are consistently present in 
lower concentrations in the brains of humans. In particular, metabolites downstream of 
adenylosuccinate lyase, which catalyzes two reactions in purine synthesis, occur at lower 
concentrations in humans. This enzyme carries an amino acid substitution that is present in 
all humans today but absent in Neandertals. By introducing the modern human substitution 
into the genomes of mice, as well as the ancestral, Neandertal-like substitution into the 
genomes of human cells, we show that this amino acid substitution is responsible for much or 
all of the reduction of de novo synthesis of purines in humans.  
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Modern humans differ dramatically from their closest evolutionary relatives in a number of 
ways. Most strikingly, they have developed rapidly changing and complex cultures that have 
allowed them to become more numerous and widespread than any other primates and closely 
related hominins such as Neandertals. This unique historical development has at least to some 
extent biological roots. However, although large numbers of traits have been identified as 
being unique to humans or been suggested to be so (e.g. (Tomasello, 2019); (Varki and 
Altheide, 2005)), it has proven difficult to identify the genetic and biological underpinnings 
of such traits. One reason may be that many of them are genetically complex (Phillips, 2008) 
and represent differences in degree rather than absolute differences between humans and 
other groups. In particular, it is unclear if any single nucleotide substitution that occurs in all 
or almost all humans today, but is not seen among the closest evolutionary relatives of 
present-day humans, the Neandertals and Denisovans (Pääbo, 2014), has biological 
consequences.  
To identify traits that may have comparatively simple genetic architectures yet 
influence the biology of modern humans, we focus here on metabolic differences. By 
analyzing the metabolomes of muscle, kidney and three different regions of the brain from 
humans, chimpanzees and macaques, we find that many aspects of amino acid metabolism 
differ between humans and the other two primates in all tissues analyzed. Among metabolic 
pathways, oxidative phosphorylation is less active in the brains of humans than the other 
primates and purine biosynthesis is less active in the human brain as well as in other tissues. 
In purine biosynthesis, we find that metabolites downstream of the enzyme adenylosuccinate 
lyase [ADSL (EC 4.3.2.2)] occur at lower concentrations in humans than in the other 
primates. ADSL carries an amino acid substitution that is unique to modern humans relative 
to apes and Neandertals and Denisovans (Castellano et al., 2014) and has been shown to 
affect the stability of the enzyme (Van Laer et al., 2018). By introducing the modern human-
like substitution in the genome of mice, and the ancestral, Neandertal-like substitution in the 
genomes of human cells, we show that this substitution is responsible for much or all of this 
metabolic change in present-day humans.  
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Metabolite changes unique to humans. To identify metabolites that have changed their 
concentration in humans relative to monkeys and apes, we measured compound 
concentrations in prefrontal cortex, primary visual cortex, cerebellum, skeletal muscle and 
kidney in four humans, four chimpanzees, and four macaques using mass spectrometry 
coupled with capillary electrophoresis (CE-MS), a technique suitable for detection of small 
hydrophilic compounds. The number of metabolites annotated in the five tissues varied 
between 166 and 197, 160 and 209, and 145 and 192 in the three species, respectively 
(Supplementary Table 1).  
 In each tissue, we identified metabolites that did not differ significantly in 
concentrations between the macaques and the chimpanzees, but differed significantly, and in 
the same direction, between humans and macaques as well as between humans and 
chimpanzees. Whereas we find no such metabolites in skeletal muscle and kidney, we find 
metabolites that differ in their concentration in humans relative to the other two primates in 
two of the three parts of the brain analyzed.  
 In cerebellum, 22 metabolites have higher concentrations in humans whereas no 
metabolites have lower concentrations (Supplementary Table 2). Eighteen of the 22 
metabolites are amino acids. In prefrontal cortex we detected five metabolites with lower 
concentrations in humans and none with higher concentrations (Supplementary Table 2). 
Three of the five metabolites are purines (inosine monophosphate (IMP), guanosine 
monophosphate (GMP), adenosine monophosphate (AMP)) and the other two are NAD+ and 
UDP-N-acetylglucosamine. 
Metabolic pathways. To identify metabolic pathways that may be more or less active in 
humans than in other primates, we linked metabolites with higher or lower concentrations in 
humans compared to both chimpanzees and macaques (even if not significantly so) to genes 
and metabolic pathways using the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
database. Supplementary Tables 3a and b give pathways that contain more genes than 
expected (p<0.01) that are associated with metabolites present in either higher or lower 
concentrations in each of the five tissues.  
 Between 8 and 12 pathways are associated with higher metabolite concentrations in 
the five human tissues (Supplementary Table 3a). All eight pathways identified in the 
prefrontal cortex involve amino acid metabolism, eight out of nine pathways in the visual 
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cortex and nine out of ten in the cerebellum also involve amino acids. In muscle and kidney, 
seven and five of the eleven and twelve pathways identified, respectively, involve amino acid 
metabolism. Thus, several aspects of amino acid metabolism seem to be increased in humans 
relative to other primates.  
 Between four and eleven pathways are associated with lower metabolite 
concentrations in the five tissues (Supplementary Table 3b). Amino acid and peptide 
metabolism make up one to five of these pathways in the different tissues, suggesting that 
amino acid metabolism has changed in several ways in humans relative to the other primates. 
Hence, metabolites in these pathways are present in increased as well as decreased 
concentrations, often in the same pathways. For example, significant numbers of metabolites 
in arginine and proline metabolism are present in higher concentrations while other 
metabolites in the same pathways are present in lower concentrations, sometimes in the same 
tissues, suggesting that the flux through these pathways has changed.  
 In contrast, metabolites in two pathways are consistently present at lower rather than 
higher concentrations in humans. One of these pathways is oxidative phosphorylation, which 
show decreased metabolite concentrations in all three brain regions analyzed. Because 
oxidative phosphorylation is not affected in muscle and kidneys, it seems that the human 
brain differs from ape brains in that oxidative phosphorylation in mitochondria is less active.  
 The second pathway that stands out is purine biosynthesis where a number of 
metabolites are present at lower levels in all five tissues analyzed. Thus, purine biosynthesis 
is decreased in humans relative to apes in the brain as well as in other organs. If we focus on 
a more restrictive definition of purine biosynthesis (Marie et al., 2004), a significant decrease 
is seen only in the three brain regions and not in muscle and kidney (Figure 1a). Furthermore, 
three of the five metabolites, IMP, GMP and AMP, which individually show significantly 
human-specific concentration decreases, are products of de novo purine biosynthesis. Thus, 
purine biosynthesis stands out as down-regulated in humans, particularly in the brain.  
Adenylosuccinate lyase (ADSL) in modern humans. The enzyme adenylosuccinate lyase 
(ADSL) catalyzes two reactions in de novo purine biosynthesis (Ciardo et al., 2001; Jaeken 
and Van Den Berghe, 1984). First, it cleaves succinylaminoimidazole carboxamide ribotide 
(SAICAR) into aminoimidazole carboxamide ribotide (AICAR) and fumarate. Second, it 
cleaves adenylosuccinate (S-AMP) into adenosine monophosphate (AMP) and fumarate 
(Figure 1a). The compounds AMP, IMP, and GMP that are reduced in the three human brain 
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regions analyzed are situated downstream of ADSL, consistent with the hypothesis that a 
change in ADSL may have caused the reduction in purine biosynthesis. 
 ADSL (Ariyananda et al., 2009) is a homotetrameric complex where three monomers 
contribute to each of the four active sites (Brosius and Colman, 2002). The gene encoding 
ADSL in humans is located on chromosome 22q13.1–13.2 and is one of only about a hundred 
protein-coding genes that carry substitutions inferred to change amino acids that are fixed or 
almost fixed in present-day humans but occur in their ancestral, ape-like state in the genomes 
of the closest extinct relatives of modern humans, Neandertals and Denisovans (Pääbo, 
2014). The substitution in ADSL in modern humans is an alanine to valine substitution at 
position 429 (A429V). Neandertals, Denisovans, all other primates and most mammals carry 
an alanine residue at this position (Figure 1b). The substitution is located in a protein domain 
that forms part of the substrate channel over the active site of the enzyme. Amino acid 
substitutions close to this position cause lowered enzymatic activity	and/or lower enzyme 
stability and result in symptoms that include psychomotor retardation, autism, and epilepsy 
(Jurecka et al., 2015; Spiegel et al., 2006; Zikánová et al., 2010) as well as alterations in brain 
structure as seen by magnetic resonance imaging (Jurecka et al., 2012). This raises the 
possibility that the amino acid substitution at position 429 may have changed the activity of 
ADSL in modern humans after their separation from the lineage leading to Neandertals and 
Denisovans.  
A mouse humanized for Adsl. To investigate how the A429V substitution may affect purine 
biosynthesis, we introduced this mutation into the Adsl gene of a C57BL/6N mouse by 
injection of the relevant oligonucleotide and CRISPR-Cas9 into the male pronucleus of 
fertilized oocytes. Adjacent to the amino acid of interest, at position 428, mice carry an 
arginine residue whereas primates carry a glutamine residue (Figure 1b). To avoid possible 
effects of the rodent-specific arginine residue at position 428 on the function of the amino 
acid at position 429, we introduced a nucleotide substitution resulting in an R428Q 
substitution in addition to the V429A substitution in the Adsl gene. The two mutations 
segregate in Mendelian ratios in the mice, and animals heterozygous and homozygous for the 
two substitutions show no overt phenotypic difference to their wild type littermates.  
ADSL activity in the humanized mice. We analyzed the enzymatic activities of ADSL in 
tissue extracts prepared from mice homozygous for the human-like mutations and their wild-
type littermates in cerebellum, cerebral cortex, heart, kidney, liver, lung, muscle, spleen and 
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testis in 12-week-old mice and (except testis) in one-week-old mice by measuring the 
conversion of adenylosuccinate to AMP.  
 In the wild-type adults, mean ADSL activity varied from 1.95 nmole/min/µg in liver 
to 24.4 nmole/min/µg in muscle (Figure 2). In the pups, mean enzymatic activity was 5.4% to 
57% higher in most tissues and largely paralleled those of the adults. Two exceptions were 
cerebellum and muscle, where ADSL activity was 41% and 11% lower in the pups than in the 
adults, respectively.  
 In the humanized mice, ADSL activity was reduced by 8.7 to 56% in all organs in 
both adults and pups (p<0.05) (Figure 2). The relative reduction of the activity in the 
humanized relative to the wild-type mice is higher in cerebral cortex (43% in pups and 56% 
in adults) than in the other tissues (8.7% - 40%). Thus, young as well as adult mice that carry 
an ADSL enzyme humanized at positions 428 and 429 have lower ADSL activity in most or 
all tissues. 
The metabolome of humanized Adsl mice. We next analyzed the metabolomes of the nine 
tissues from 9-12 adult homozygous humanized mice and their wild-type littermates by gas 
chromatography coupled with mass spectrometry (GC-MS). We similarly analyzed eight 
tissues (no testis) from 10-12 one-week-old pups (Supplementary Table 4). The number of 
metabolites detected varied between 176 and 273 in the adult mice and between 310 and 347 
in the young mice. Among those, an average of 280 (median = 273) were detected in at least 
50% of the adult and young individuals in each of the nine tissues (Supplementary Table 
5a,b). A principle component analysis using the concentrations of all metabolites detected 
revealed one to two outlier samples per tissue (Supplementary Table 4). These were excluded 
from further analyses. Including these samples in the analyses did not qualitatively affect 
results. 
 Among the organs analyzed, only the brain showed significant differences in 
metabolite concentrations between the wild type and humanized mice. Specifically, 36 
metabolites showed significant concentration differences in cerebellum of 12-week-old mice 
(permutations, p = 0.036) and 45 metabolites showed marginally significant differences in the 
cerebral cortex of one-week-old mice (permutations, p = 0.081, Supplementary Table 6). 
Thus, the metabolic effects of the two mutations introduced in ADSL are particularly 
pronounced in the central nervous system.  
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 The concentration differences detected in cerebellum of the 12-week-old mice 
correlated with differences observed in cerebral cortex, even though differences in cortex did 
not pass the significance cut-off in the permutation test (Pearson correlation, r = 0.84, p < 
0.0001, n = 29; Supplementary Fig. 1a). Similarly, concentration differences detected in 
cerebral cortex in one-week-old mice correlated with differences observed in cerebellum in 
the same mice (Pearson correlation, r = 0.77, p < 0.0001, n = 45; Supplementary Fig. 1b). 
The concentration differences between wild type and humanized mice furthermore correlated 
between the one-week-old and 12-week-old mice both in cortex and in cerebellum (Pearson 
correlation, r = 0.49 and r = 0.52, p < 0.008, n = 28 and n = 31, respectively; Supplementary 
Fig. 1e, f). By contrast, the correlation between metabolic differences detected in brain and 
the other tissues was weaker (p < 10-8 for brain tissues and p > 10-4 for other tissues) (p < 10-
8; Supplementary Fig. 1c,d). Thus, in the humanized mouse, the effects of the substitutions in 
ADSL are seen in the cerebral cortex and cerebellum in both young and adult animals. 
Purine biosynthesis in the humanized mice.  In the 12-week-old mice, we detected six 
metabolites within the purine biosynthesis pathway. In the humanized mice, four of these 
metabolites had lower concentrations than in the wild-type mice in the cerebral cortex and all 
of them had lower concentrations in the cerebellum (binomial test for cortex and cerebellum, 
p = 0.04) (Figure 3).  
 The six metabolites detected in 12-week-old mice were also detected in the primate 
brains. Four of these had lower concentrations in the human brain, including AMP and GMP 
in prefrontal cortex, the visual cortex, and in cerebellum (binomial test, p = 0.04). 
Furthermore, four of the six metabolites with lower concentrations in cerebellum in the 
humanized mice had lower concentrations in human cerebellum compared to other primates: 
AMP, GMP, inosine, and adenine (Figure 3). In the one-week-old mice, we detected 7 
metabolites in the purine biosynthesis pathway. In the humanized mice, five of these had 
lower concentration in the cerebral cortex and three of these had lower concentration in the 
cerebellum when compared to their wild-type litter mates (Supplementary Fig. 2). 
 Thus, several changes in concentrations of compounds in purine biosynthesis seen in 
the humanized mice recapitulate differences seen when the metabolomes of human brains are 
compared to the brains of chimpanzees and macaques. 
Activity and stability of humanized mouse ADSL. To investigate how the humanized form 
of the mouse ADSL enzyme may influence purine biosynthesis, we synthesized mouse wild-
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type (wt) ADSL and mouse A429V ADSL and inserted them in expression vectors that 
include N-terminal polyhistidine tags (pET-14b vector) (Lee and Colman, 2007). We 
analyzed the conversion of SAICAR to AICAR, and the conversion of SAMP to AMP, in the 
presence of excess substrate by measuring the rate of production of AICAR and AMP (Figure 
4a) and found no differences in the kinetics of either reaction between wt and A429V ADSL 
(t-test, p>0.05).  
 We next investigated if the A429V substitution, and/or the R428Q substitution that 
was introduced into the humanized mice together with the A429V substitution, affect the 
conformational stability of the protein by constructing expression vectors that carry wild-type 
murine ADSL, ADSL with only the A429V substitution, ADSL with only an R428Q 
substitution, and ADSL with the A429V substitution and the adjacent R428Q substitution. 
We then compared the secondary structure stability of all four protein variants by measuring 
the circular dichroism spectra of the purified proteins at 222 nm while heating them from 55 
°C to 80 °C at a rate of one degree per minute (Figure 4b). Mouse ADSL protein with alanine 
at position 429 was more stable (50% folded at 68.3 °C, +/-0.3 °C, n=4) than mouse ADSL 
protein with valine at position 429 (50% folded at 67.3 °C +/-0.3 °C, n=4). The effect on the 
protein stability of the A429V substitution was not influenced by the presence or absence of 
the adjacent R428Q substitution at position 428. In summary, the A429V substitution does 
not affect the kinetics of the murine ADSL enzyme. However, it decreases the secondary 
structure stability of the protein. 
Characterization of human and Neandertal ADSL. Previous work has shown that the 
modern human version of ADSL is less stable than the ancestral, Neandertal-like form in 
vitro (Van Laer et al., 2018). To ensure that the two forms of the ADSL protein which differ 
only at position 429 in the protein are both enzymatically active in living cells we show that 
they both are able to rescue Chinese hamster ovary cells that lack ADSL activity (AdeI cells, 
(Vliet et al., 2011)) (Supplementary Fig. 3a). We then expressed the modern human and 
Neandertal versions of ADSL in E. coli and isolated the two proteins by N-terminal His-tags 
(Lee and Colman, 2007). In agreement with previous results (Van Laer et al., 2018), circular 
dichroism spectra of both protein versions exhibited predominantly alpha-helical 
characteristics (Supplementary Fig. 3b). To investigate if the enzymatic activities of the 
human and Neandertal versions of ADSL differ, we tested their ability to convert SAICAR to 
AICAR, and SAMP to AMP, as described above. No differences in specific activity between 
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the two enzymes were detected using either substrate (SAMP, t-test, p=0.41 or SAICAR, t-
test, p=0.81, Figure 5a). 
 To investigate if cooperativity between the two activities of ADSL may be affected by 
the A429V substitution, we incubated the two forms of the enzyme with equimolar amounts 
of SAMP and SAICAR and calculated relative values of ADSL protein activity when 
presented with a single substrate (Figure 5a) or an equimolar mixture of SAMP and SAICAR 
(Figure 5b). The conversion of SAMP to AMP is reduced approximately to the same extent 
(~2.4-fold, t-test, p=0.49) for the modern human and Neandertal-like forms of the enzyme 
when both substrates are present (Figure 5d). In contrast, the conversion of SAICAR to 
AICAR is reduced about 1.8-fold for the modern human form in the presence of both 
substrates (p=0.026) while the ancestral form of the enzyme shows no reduction (Figure 5c) 
(p=0.44). This suggests that the modern human enzyme produces less AICAR than the 
ancestral enzyme under physiological conditions and may warrant further investigation. 
Stability of modern human and ancestral ADSL. To investigate the effects of the A429V 
substitution in the human protein, we compared the stability of the secondary structure of the 
protein as described above. The temperature at which 50% of the protein is inferred to be 
folded is 67.0 °C (+/-SEM=0.10 °C) for the modern human form of the protein and 68.0 °C 
(+/-SEM=0.2 °C) for the Neandertal-like form of the protein (Figure 6a). Thus, as previously 
shown (Van Laer et al., 2018), modern human ADSL is less stable than ancestral ADSL. 
 To investigate the effect of the difference in secondary structure stability on the 
stability of ADSL quaternary structures, we exposed the proteins to 0.75M, 0.90M, 1.0125M, 
1.125M and 1.5M guanidine hydrochloride (GdnHCl) overnight at room temperature and 
analyzed the proteins by native gel electrophoresis. Bands corresponding to the predicted size 
of the ADSL tetramer (~223 kDa) and monomer (~56 kDa) were observed and the relative 
proportion of tetrameric protein was estimated. Figure 6b shows that at 1.0125 M GdnHCl 
about 50% of the modern human version of ADSL was present as tetramers whereas for the 
ancestral form this was the case at 1.125 M GdnHCl. Thus, both the secondary and 
quaternary structures of the ancestral form of ADSL are more stable than for the modern 
human form. 
Ancestralized ADSL in human cells. To investigate how the A429V substitution affects the 
metabolome of living human cells, we used CRISPR-Cas9 to introduce the nucleotide 
substitution in the ADSL gene that reverts the valine at position 429 to the ancestral alanine 
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residue in human 409B2 cells (Riken BioResource Center). We isolated three independent 
cell lines and we verified that the intended nucleotide substitution had occurred in each of 
them by sequencing a segment of the ADSL gene and excluded deletions of the target site by 
quantitative PCR (not shown). We also isolated six independent lines that had been subjected 
to the CRISPR-Cas9 procedure but did not exhibit any mutation in the sequenced DNA 
segment. We expanded 10 separate cultures of the three edited cell lines and 19 cultures of 
the control lines. Each of these cultures were analyzed by LC-MS in positive and negative 
modes.  
A total of 10,673 metabolites were detected. Among these were twelve metabolites 
from the de novo purine biosynthesis pathway and three of these (aminoimidazole 
ribonucleotide (AIR), hypoxanthine, guanine) were present at significantly lower amounts in 
the wild type versus the ancestralized cells (p<0.01). Strikingly, out of nine detected 
metabolites downstream of ADSL, all have lower concentrations in the wild type cells 
(binom. test, p = 0.002, Figure 7). Thus, in human cells, the ancestral form of ADSL supports 
a higher level of purine biosynthesis than the modern human form. 
Comparison to chimpanzee cells. To compare these results to purine biosynthesis in 
chimpanzees, we similarly analyzed nine cultures from three different chimpanzee 
pluripotent cell lines. Out of 1,286 metabolites that differ significantly (p<0.01) between the 
human and chimpanzee wild type cells, three purine biosynthesis metabolites (AIR, 
guanosine, guanine) are at higher concentrations in the chimpanzee cells. The same nine 
metabolites as in the comparison to the ancestralized human cells were detected in the 
chimpanzee cells. Similar to the ancestralized human cells, they are present in lower 
concentrations in the human than in the chimpanzee cells (binom. test, p = 0.002, Figure 7).  
Thus, reversal of the A429V substitution in ADSL in human cells results in an increase in 
purine biosynthesis similar to what is observed when chimpanzee cells are compared to 
human cells. 
AMPK dephosphorylation. One way in which lower steady state levels of metabolites 
downstream of ADSL in purine biosynthesis may affect cells is through activation of the 
AMP-activated protein kinase (AMPK). This serine/threonine protein kinase complex is 
composed of a catalytic α-subunit, a scaffolding β-subunit and a regulatory γ-subunit. Of 
particular relevance may be phosphorylation of the threonine at position 172 in the α-subunit 
[pAMPKα(Thr172)], which is enhanced when AMP is bound by the γ-subunit (Davies et al., 
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1995) (Hawley et al., 1995). AICAR, a direct product of ADSL and an intermediate in the 
generation of IMP and AMP, can mimic AMP in stimulating AMPK activity (Daignan-
Fornier and Pinson, 2012; Kim et al., 2016; Mihaylova and Shaw, 2011). As SAICAR to 
AICAR catalysis (Figure 5c) as well as AMP levels (Figure 7) are reduced in human cells, 
phosphorylation of AMPKα(Thr172) may be reduced, and its activity decreased. 
 To test if this is the case, we measured the levels of phosphorylated AMPKα(Thr172) 
in two wild type human and two ancestralized cell lines by immunoblotting with antibodies 
specific to pAMPKα(Thr172) and to total AMPKα. The levels of phosphorylated 
AMPKα(Thr172) were 28.5% higher in the ancestralized cells than in the wild type human 
cells (p=0.04) (Figure 8a) and the ratio of phosphorylated AMPKα to total AMPKα was 
10.3% higher in the ancestralized cells (p=0.10), consistent with the hypothesis that higher 
levels of AICAR and AMP in the ancestralized human cells may increase the 
phosphorylation of AMPK. Next, we compared the pAMPKα(Thr172) levels in three human 
and three chimpanzee cell lines. The levels of phosphorylated AMPKα(Thr172) were 59.3% 
higher in the chimpanzee than human the cells (p=0.03) (Figure 8b), while the ratio of 
phosphorylated AMPKα to total AMPKα was 47.9% higher in the chimpanzee cells 
(p=0.002). Thus, ancestralization of position 429 in ADSL in human cells reduces purine 
biosynthesis and phosphorylation of threonine at position 172 in the α-subunit of AMPK and 
both effects are qualitatively similar to differences seen when chimpanzee and human cells.  
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The ancestors of modern humans diverged from their closest evolutionary relatives, 
Neandertals and Denisovans, on the order of 600,000 years ago (Prüfer et al., 2014). About 
ten times further back the ancestors of hominins diverged from the ancestors of chimpanzees 
and bonobos (Langergraber et al., 2012). Whereas most phenotypic features that distinguish 
present-day humans from the apes and from their extinct hominin relatives are likely to be 
genetically complex, metabolic differences may sometimes have a comparatively simple 
genetic background because genomic changes that affect genes encoding enzymes may affect 
flux in metabolic pathways.  
 To find metabolic differences that set humans apart from their closest evolutionary 
relatives we investigated the metabolomes of the brain, muscle and kidney in humans, apes 
and monkeys. Whereas we find no such differences among the metabolites analyzed in 
muscle and kidney, in the brain, steady state concentrations of many compounds involved in 
amino acid metabolism are present in higher or lower levels in humans versus other primates. 
In the future, it may be of interest to investigate the consequences of these human-specific 
metabolic features for the synthesis and catabolism of amino acids. 
 Oxidative phosphorylation and purine biosynthesis stand out in that metabolites in 
both pathways are present in lower concentrations in humans than in the other primates 
analyzed. Whereas oxidative phosphorylation is lower in the three brain regions analysed but 
not in muscle and kidney, purine biosynthesis is decreased in all tissues analysed, although 
most drastically in brain.  
Humans and apes diverged so long ago that almost every gene carries changes that 
potentially alter its function by affecting its regulation or the structure of the encoded gene 
product. In contrast, modern humans and Neandertals and Denisovans diverged so recently 
that for about 90% of the genome, the two archaic human groups fall within the variation of 
present-day humans (Green et al., 2010). Furthermore, when modern and archaic humans met 
about 50,000 years ago, they interbred. This resulted in that Neandertal DNA fragments that 
together make up about half of the Neandertal genome exist in present-day humans 
(Sankararaman et al., 2014). The number of proteins that carry amino acid substitutions in all 
or almost all humans that differ from Neandertals and apes is therefore only about one 
hundred (Pääbo, 2014). It is unclear if any of these substitutions have any functional 
consequences. 
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The alanine to valine substitution at position 429 in ADSL is one of this small number 
of substitutions. It is particularly likely to have functional consequence. Position 429 is 
conserved as alanine in most tetrapods suggesting that it may be of importance. Position 429 
is also located only three positions away from position 426, where an arginine to histidine 
substitution causes the most common form of adenylosuccinase deficiency in present-day 
humans (Edery et al., 2003; Kmoch et al., 2000; Maaswinkel-Mooij et al., 1997; Marie et al., 
1999; Race et al., 2000). Further evidence suggesting that a change in ADSL may have been 
of importance in the evolution of modern humans comes from a screen for genomic regions 
that have experienced selective sweeps in humans after their split from Neandertals but 
before the separation of Africans and Eurasians (Racimo, 2016). In that study, a genomic 
region centered around ADSL is among the top 20 candidate regions, although it contains also 
other genes. Furthermore, previous work has shown that the A429V substitution reduces the 
thermal stability of the ADSL protein in vitro (Van Laer et al., 2018). We therefore decided 
to analyze if it might be involved in the reduced purine biosynthesis seen in present-day 
humans by investigating the function of the ancestral, Neandertal-like and the derived, 
modern human-like forms of ADSL in vitro and in vivo. 
We confirm the previous finding (Van Laer et al., 2018) that the A429V substitution 
does not affect the kinetic properties of the ADSL enzyme but decreases its thermal stability 
and show that the substitution also decreases the stability of the tetrameric complex of the 
enzyme. When introduced in the mouse ADSL protein in conjunction with a primate-specific 
substitution at the adjacent position 428, it reduces the enzymatic activity detected in nine 
tissues analyzed, most drastically in the brain, and results in a reduction in purine 
biosynthesis, thus recapitulating differences seen between humans and chimpanzees and 
macaques.  
To investigate how the A429V substitution may affect the metabolism of human cells, 
we used CRISPR-Cas9 to introduce the ancestral, Neandertal-like substitution into human 
cells. The concentrations of all nine metabolites detected downstream of ADSL in purine 
biosynthesis are increased in human cells carrying the ancestral substitution. In chimpanzee 
cells, the same nine metabolites are similarly increased. Notably, the expression of ADSL 
messenger RNA does not differ between human and chimpanzee cells, nor between wild type 
and ancestralized cells (not shown). Thus, the A429V substitution is responsible for much or 
all of the difference in purine biosynthesis observed when human tissues are compared to ape 
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and monkey tissues, indicating that this change in metabolism occurred in humans after their 
separation from the ancestor shared with Neandertals and Denisovans.  
An interesting question is what downstream effects a reduced purine biosynthesis in 
modern humans might have. In this regard, it is of interest that the A429V substitution 
correlates with reduction in phosphorylation of AMPK, a major regulator of cellular energy 
homeostasis. It is possible that reduced AMPK activity may contribute to the reduction in 
oxidative phosphorylation seen in human brains through its direct effects on this pathway 
(Lantier et al., 2014; Nam et al., 2016) and/or through its effects on the generation of 
mitochondria in cells (Bergeron et al., 2001; Jäger et al., 2007; Marin et al., 2017; Reznick et 
al., 2007). However, we find no evidence that oxidative phosphorylation is affected in the 
ancestralized human cells nor in the mice carrying the human substitution. Thus, if the 
A429V substitution contributes to a reduction in oxidative phosphorylation in humans, it 
presumably does so in conjunction with other genetic changes.  
In general, it is interesting that although ADSL is expressed and functions in all 
tissues, the down-regulation of purine biosynthesis in humans relative to apes, and in 
humanized mice relative to wild-type mice, is most pronounced in the brain. It is also 
interesting that mutations in humans that affect enzymes involved in purine metabolism have 
more pathological consequences in the nervous system than in other organs (Fumagalli et al., 
2017; Micheli et al., 2011).	It is thus possible that the A429V substitution in ADSL has 
contributed to human-specific changes in brain development and function. Future work will 
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dissection, mouse genome editing, genome editing in human cells, enzyme essays, mass 
spectrometric metabolite measurements, protein properties assessment, and statistical analysis 
are described in detail in Supplementary Information. 
 
  
.CC-BY-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted May 13, 2020. . https://doi.org/10.1101/2020.05.11.087338doi: bioRxiv preprint 
19	
	







Figure 1. Human-specific differences of metabolite levels in purine biosynthesis 
pathway and ADSL protein sequence. a. Purine biosynthesis in humans relative to apes. 
Pathway sketch illustrating the central role of ADSL in purine biosynthesis and showing the 
human-specific changes when compared to chimpanzees and macaques in metabolite 
concentrations in three brain regions as detected by CE-MS. PFC – prefrontal cortex, PVC – 
primary visual cortex, CB – cerebellum. b. Partial amino acid sequences of ADSL.	Accession 
numbers and amino acid sequences are from NCBI. X-ray structural determination of ADSL 
(4FFX) is from (Ray et al., 2012). 
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Figure 2. ADSL activity in tissues from humanized and wild type mice. a. One-week-old 
mice. b. Twelve-week-old mice. Conversion of adenylosuccinate to AMP was monitored by 
measuring λ 282 nm absorbance over 20 minutes (see Methods). 
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Figure 3. Purine biosynthesis in adult mice “humanized” for ADSL. Pathway sketch 
showing changes in metabolite concentrations as detected by CE-MS in mice carrying the 
V429A and R428Q substitutions in the ADSL protein. PFC – prefrontal cortex, CB – 
cerebellum. Metabolites that are also present in lower concentrations in human cerebellum 
than in chimpanzee are on blue background. 
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Figure 4. Characterization of mouse ADSL forms. a. Enzyme kinetics tested in excess of a 
substrate for the products (AICAR and AMP, see text above the plots) with one substrate 
(single) or with both substrates (mixed) in the reaction mix. Specific activity of wild type and 
humanized A429V versions do not differ (P>0.05, t-test). b. Protein melting measured by CD 
at 222nm for mouse WT (RA), mouse RV, mouse QA and mouse QV ADSL versions. The 
RV (p=0.10, t-test) and QV versions (p=0.05, t-test) are less stable.  
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Figure 5. Specific activity and cooperativity of human and ancestral ADSL versions. 
Specific activity of SAMP to AMP and SAICAR to AICAR conversions for the Neandertal-
like (red) and modern human (blue) forms of ADSL when incubated with each substrate 
separately a, or with both substrates (“mixed”) b (P>0.05, t-test). (c and d) Changes in 
enzyme cooperativity between ancestral and human versions given as the ratios of activities 
in presence of single substrates to both substrates. The human version show a higher 
reduction of activity for SAICAR to AICAR conversion in the presence of both substrates 
than the ancestral version (t-test, p=	0.01) c, which is not seen for SAMP to AMP conversion 
d (t-test, p=	 0.49). Bars represent average values over 3 repetitions, error bars represent 
standard errors.   
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Figure 6. Stability of modern human and Neandertal-like ADSL. a. Thermal denaturation 
as observed as CD at 222nm for 55oC-75oC (plot insert) and enlarged for 62-72oC (bigger 
panel) indicate lower stability of the modern human ADSL at the denaturation midpoint (t-
test, p=0.001). b. Chemical denaturation observed by native gel electrophoresis (p=0.024 for 
1.125M Gdn-Hcl concentration, t-test with Bonferroni correction). Plot represents average 
amount of tetrameric protein over 5 repetitions. Error bars represent standard errors.  
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Figure 7. Purine biosynthesis in human cells carrying the V429A substitutions and 
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Figure 8. Total AMPK and phosphorylated AMPKα(Thr172) in ancestralized human 
and chimpanzee cells. a. Results for two wild type (WT) cellular clones (253-61, 199-7) and 
two cellular clones (ADSL36, ADSL55) carrying the V429A substitutions (Mut) are shown, 
as well as the ratios of the quantitation of the proteins. b. Results for three human and three 
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